Wordt geladen...
Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial
BACKGROUND: The approval of extended release injectable naltrexone (XR-NTX; Vivitrol®) has introduced a new option for treating opioid addiction, but studies are needed to identify its place within the spectrum of available therapies. The absence of physiological opioid dependence is a necessary and...
Bewaard in:
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4017322/ https://ncbi.nlm.nih.gov/pubmed/24602363 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drugalcdep.2014.02.002 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|